For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | - | 0 | - | - |
| Research and development | 943,478 | 1,025,547 | 1,573,928 | 1,400,564 |
| General and administrative | 886,055 | 2,346,323 | 596,886 | 328,995 |
| Legal and professional | 437,409 | 538,536 | 780,427 | 1,322,002 |
| Total operating expenses | 2,266,942 | 3,910,406 | 2,951,241 | 3,051,561 |
| Net loss from operations | -2,266,942 | -3,910,406 | -2,951,241 | -3,051,561 |
| Interest expense-Related Party | 721 | 2,614 | - | - |
| Change in fair value of marketable securities | - | 0 | - | - |
| Interest expense-Nonrelated Party | 18,183 | 19,129 | - | - |
| Loss on settlement of convertible debt | - | 0 | - | 762,186 |
| Interest income | 486 | 81 | - | 2,524 |
| Change in fair value of marketable securities | - | - | - | -42,898 |
| Interest expense | - | - | 11,930 | 2,137 |
| Gain on sale of marketable securities | - | 0 | - | 56,398 |
| Change in fair value of derivative liabilities | 2,427 | 11,673 | 2,643 | 286,316 |
| Change in fair value of convertible notes | -64,369 | 213,930 | -92,479 | - |
| Total other (expense) income | -80,360 | 203,941 | -101,766 | -732,521 |
| Net loss | -2,347,302 | -3,706,465 | -3,053,007 | -3,784,082 |
| Net loss per shares - basic | -1.05 | -3.29 | -0.3 | -1.59 |
| Net loss per shares - diluted | -1.05 | -3.29 | -0.3 | -1.59 |
| Weighted average common shares outstanding - basic | 2,233,650 | 1,126,054 | 10,048,915 | 2,384,177 |
| Weighted average common shares outstanding - diluted | 2,233,650 | 1,126,054 | 10,048,915 | 2,384,177 |
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)